102 lines
4.2 KiB
HTML
102 lines
4.2 KiB
HTML
{{define "nav"}}
|
|
<div>
|
|
<p class="sidebar-label">subjects</p>
|
|
<div class="skill-list">
|
|
<div class="skill-item">opinion</div>
|
|
<div class="skill-item">due diligence</div>
|
|
<div class="skill-item">performance</div>
|
|
</div>
|
|
</div>
|
|
|
|
{{end}}
|
|
|
|
{{define "body"}}
|
|
<section class="hero" id="about">
|
|
<p class="hero-eyebrow">Equity Research · 2026</p>
|
|
<h1 >Fundamental<br><span>value exploration</span>
|
|
</h1>
|
|
<p class="hero-bio">
|
|
|
|
The truth I keep coming back to is simple: find value grounded in the fundamental numbers of a company.
|
|
<br>
|
|
My approach is rooted in fundamental analysis using SEC filings (10-K, 10-Q), earnings reports, profitability, liquidity, risk factors, and long-term business sustainability. In low-transparency situations I rely on structured cross-validation across sources.
|
|
<br>
|
|
A pattern I keep seeing is CEOs speaking just close enough to reality to generate a short-term price boost, then moving the goalposts when reality catches up. What companies state in filings and what they communicate to retail or even professional investors can be two very different stories. Guidance only needs to reach far enough into the future to say almost anything.
|
|
|
|
</p>
|
|
|
|
</section>
|
|
|
|
<section id="research">
|
|
|
|
|
|
|
|
<div class="section-head">
|
|
<h2>Current stock analysis</h2>
|
|
</div>
|
|
<p class="hero-bio">
|
|
The reports listed are what I still consider actionable and aligned with my opinion on the given company at this time. Understand that the information and the time of writing may be dated. The mispricing thesis remains valuable regardless.
|
|
|
|
<br>
|
|
Personal opinion only, not financial advice, and I'm not liable for anyone else's use of this analysis.
|
|
</p>
|
|
<br>
|
|
<div class="exp-card link" onclick="window.open('/static/pdf/mstr.pdf', '_blank')">
|
|
<div class="exp-header">
|
|
<span class="exp-title">MSTR: Strategy</span>
|
|
<div>
|
|
<span class="exp-tag">due diligence</span>
|
|
<span class="exp-tag red">Sell</span>
|
|
</div>
|
|
</div>
|
|
<p class="exp-body">
|
|
The company only owns btc by issuing debt and preferred stock offering.
|
|
<br>
|
|
The company is expensive btc at its best and ponzi scheme at its worst.
|
|
</p>
|
|
</div>
|
|
<br>
|
|
<div class="exp-card link" onclick="window.open('/static/pdf/novo.pdf', '_blank')">
|
|
<div class="exp-header">
|
|
<span class="exp-title">Novo.B/NVO: Novo Nordisk A/S</span>
|
|
<div>
|
|
<span class="exp-tag">due diligence</span>
|
|
<span class="exp-tag green">buy</span>
|
|
</div>
|
|
|
|
|
|
</div>
|
|
<p class="exp-body">
|
|
The product sales of wieght loss drugs are highclass, pipeline is undervalued.
|
|
<br>
|
|
Pipeline and wegovy pil is not reconsiced correctly as high focus on expireation of current sold product. high pessimistic view of pipeline.
|
|
</p>
|
|
</div>
|
|
<br>
|
|
|
|
<div class="section-head">
|
|
<h2>Equity portfolio performance</h2>
|
|
</div>
|
|
<p class="hero-bio">
|
|
year to date performance has its volatility/risk and statistical issues, meaning this have very little predictive power. hard to say if these numbers will continue year by year.
|
|
</p>
|
|
<br>
|
|
<div class="exp-card">
|
|
<div class="exp-header">
|
|
<span class="exp-title">Trades</span>
|
|
</div>
|
|
<div>
|
|
<p class="exp-body"> mostly long trades on NOVO, MEARSK, ORTSED and VWS with a low wieght of puts on RGTI </p>
|
|
</div>
|
|
|
|
</div>
|
|
<br>
|
|
<div class="exp-card">
|
|
<div hx-get="/static/components/eq.html" hx-trigger="load" hx-swap="outerHTML">
|
|
<span class="spinner">Loading chart...</span>
|
|
</div>
|
|
</div>
|
|
|
|
|
|
</section>
|
|
{{end}} |